Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205756 | 0.98 | MAPT (0.47) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL9613268 | 0.96 | MAPT (0.41) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL9033449 | 0.91 | NPSR1 (0.38) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL5640425 | 0.84 | KDM4E (0.39) | MAPTNPSR1ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL12049719 | 0.82 | CYP3A4 (0.38) | MAPTNPSR1ALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL12380772 | 0.78 | KMT2A (0.33) | MAPTNPSR1ALDH1A1CYP3A4KMT2A | |
| SCHEMBL7350471 | 0.76 | CYP1A2 (0.36) | ALDH1A1 | |
| SCHEMBL4825839 | 0.76 | MAPT (0.49) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL12950942 | 0.74 | MAPT (0.47) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL5526779 | 0.74 | MAPT (0.51) | MAPTNPSR1ALDH1A1L3MBTL1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210324-A1 | SUBSTITUTED CYCLOPENTENES, THEIR PREPARATION AND THEIR USE FOR CHIRAL SCAFFOLDS | Chirotech Technology Limited (GB) | 2002-06-05 | — | — | EP | claimed |
| WO-2001017952-A1 | SUBSTITUTED CYCLOPENTENES, THEIR PREPARATION AND THEIR USE FOR CHIRAL SCAFFOLDS | CHIROTECH TECHNOLOGY LIMITED (GB) | 2001-03-15 | — | — | WO | claimed |
| EP-1718617-B1 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| US-20090149463-A1 | Therapeutic agents | CHENG LEIFENG | 2009-06-11 | — | — | US | disclosed |
| WO-2007038669-A9 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC | 2008-05-29 | — | — | WO | disclosed |
| EP-1718617-A2 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080343-A2 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149463-A1 | Therapeutic agents | NLN, BDNF, GAP43 | MAPT 291/4885NPSR1 49/4885ALDH1A1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.